(Sharecast News) - Shield Therapeutics reported its strongest quarterly performance to date on Thursday, with third-quarter Accrufer prescriptions rising about 15% from the previous quarter and revenues reaching a new high, keeping the company on track to become cash flow positive by year-end.

The AIM-traded pharmaceutical group, which specialises in...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE